JPRN-UMIN000027100未知未知
Aflibercept treat and extend for macular edema secondary to branch retinal vein occlusion - Aflibercept treat and extend for branch retinal vein occlusion
Jikei daisan hospital0 个研究点目标入组 50 人开始时间: 2017年4月24日最近更新:
适应症
试验速览
- 阶段
- 未知
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Past history of vitrectomy or glaucoma surgery 2.Cataract surgery within 3 months 3.patients with diabetic retinopathy or central vein occlusion 4.IOP poor control
研究者
相似试验
进行中（未招募）
1 期
Prospective non-randomised pilot study looking at the safety and efficacy of a drug called Eylea for patients with an eye condition called Retinitis Pigmentosa, that also have swelling at the back of the eyeRetinitis Pigmentosa associated Cystoid Macular OedemaMedDRA version: 18.1 Level: PT Classification code 10038914 Term: Retinitis pigmentosa System Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2015-003723-65-GBMoorfields Eye Hospital30
招募中
不适用
Efficacy of aflibercept for Macular edema secondary to central retinal vein occlusion (CRVO)central retinal vein occlusionJPRN-UMIN000014505Asahikawa Medical University30
已完成
不适用
Efficacy of Aflibercept for macular edema in our hospitaldiabetic macular edema, retinal vein occlusionJPRN-UMIN000048108Chiba University300
招募中
4 期
Therapy of recalcitrant macular edema in aphakic and/or eyes with with severe iris-lens diaphragm disruption with longterm intravitreal steroid implants such as Iluvien® or Ozurdex®.recalcitrant macular edemaH35.8Other specified retinal disordersDRKS00020282Augenklinik des Klnikums der Ludwig-Maximilians-Universität München40
进行中（未招募）
1 期
Antibody treatment in retinal vein occulsion and the influence on oxygen and blood supplyretinal vein occlusionEUCTR2016-001660-10-ATniversitätsklinik für Augenheilkunde und Optometrie30